Tipifarnib

N/A

Report date: 2026/03/31 20:00:21
NME

Base Information

Drug NameTipifarnib
Drug Alias Name替匹法尼Tipifarnibum替吡法尼ZarnestraR-115777 +[6
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionProtein farnesyltransferase inhibitors
TargetsProtein farnesyltransferase
Therapy Area/IndicationsCNS Embryonal TumorSolid tumoursPrimary Myelofibrosis +[79
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumCanadaUnited States +[22
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesJohnson & Johnson
China Registration ClassN/A

Develop Information

Active IndicationsSolid tumoursHistiocytosis, Langerhans-CellThyroid Neoplasms +[20
Inactive IndicationsCNS Embryonal TumorPrimary MyelofibrosisMyeloproliferative Disorders +[59

Other Information

ATC CodeN/A